30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Alphatec Spine

4Q13 revenue: $53.1MM, +3% (U.S. $35.7MM, +5%; ex-U.S. $17.4MM, +1%)

  • Excluding PureGen revenue from 2012, U.S. revenue +11%
  • Minimally invasive portfolio +26%
  • U.S. hospital non-biologic revenue +20%
  • Ex-U.S. sales impacted by discontinued operations in France (was bringing in ~$1.5MM/quarter)
  • Received regulatory approval for Epicage in Brazil, Discocerv in China


2013 revenue: $204.7MM, +7% (U.S. $135MM, +3%; ex-U.S. $69.8MM, +15%: Japan $28.4MM, +19%)

  • Minimally invasive portfolio +20% (Illico MIS +19%)
  • Excluding PureGen revenue from 2012, U.S. revenue +8%
  • U.S. revenue supported by continued unit volume growth with core hospital business, growing product adoption; ex-U.S. growth driven by Japan, expansion within China and Latin America
  • >27% of 2013 revenue attributed to targeted marketing/sales initiatives
  • Strong uptake for Solus ALIF
  • Zodiac Direct Vertebral Rotation buoyed strong double-digit growth in U.S. deformity
  • ~30% of biologics revenue from new products (e.g., NeXoss, Profuse Bioscaffold Allograft)
  • Reached global settlement agreement with OrthoTec for $49MM in case against Surgiview
  • Claims #4 market share position in Japan
  • Trained ~400 surgeons
  • Physician owned distributor business accounted for under 5%


2014 revenue forecast: $208MM-$215MM